Dr. Katrina S. Wade, MD
Gynecologic Oncology (Gynecologic Oncology Physician)
1514 Jefferson Hwy
New Orleans, LA 70121
Who else practices at this address →
Jefferson Parish includes primary care (18% of residents) shortage areas. About shortage areas
- Medicare participating
At a glance
- Years since graduation
- 18
- In the NPI registry since
- 2008
- Medicare patients seen, 2024
- 150
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2008Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Gynecologic Oncology Physician primary
LA license MD.203788 - Student in an Organized Health Care Education/Training Program
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Ochsner Medical Center Acute New Orleans, LA
- Slidell Memorial Hospital Slidell, LA
- St Tammany PArish Hospital Covington, LA
- Terrebonne General Medical Center - PArish Houma, LA
- Leonard J Chabert Medical Center Houma, LA
Medical groups
- Ochsner Clinic LLC (2,864 clinicians)
- South Louisiana Medical Associates (113 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 150
- Services billed
- 402
- Patients’ average age
- 71
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 30-39 minutes | 141 | 93 |
| Established patient office or other outpatient visit, 40-54 minutes | 65 | 18 |
| New patient office or other outpatient visit, 60-74 minutes | 19 | 19 |
| Removal of uterus, tubes, and/or ovaries through abdomen using an endoscope, 250.0 g or less | 12 | 12 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Dexamethasone Other prescribers in New Orleans, LA | 27 |
| Clobetasol Propionate Other prescribers in New Orleans, LA | 22 |
| Zejula (niraparib tosylate) | 15 |
| Ibuprofen Other prescribers in New Orleans, LA | 12 |
| Lenvima (lenvatinib mesylate) | 11 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 6 companies reported 13 payments worth $1,746 in total to this clinician.
| GlaxoSmithKline, LLC. | $1,345 |
|---|---|
| Merck Sharp & Dohme LLC | $171 |
| Dilon Technologies, Inc. | $141 |
| AstraZeneca Pharmaceuticals LP | $33.82 |
| AbbVie Inc. | $28.32 |
| Daiichi Sankyo Inc. | $27.31 |
| Consulting Fee | $1,269 |
|---|---|
| Food and Beverage | $477 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| GlaxoSmithKline, LLC. Jun 12, 2025 | Consulting Fee JEMPERLI · ONCOLOGY | $1,269 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 5 industry-funded studies in 2025, from 4 companies. The companies reported $91,455 in research payments for these studies, mostly to the institutions running them.
- A randomized, double-blind, phase 3 comparison of platinum-based thera
GlaxoSmithKline, LLC. - Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer
AbbVie Inc. · Active, not recruiting · NCT05445778 - A phase 3, randomized, double-blind, placebo-controlled, multicenter s
GlaxoSmithKline, LLC. - A Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy
Pharmaand GmbH · Active, not recruiting · NCT03522246 - A Study of DS-6000a in Subjects With Advanced Renal Cell Carcinoma and Ovarian Tumors
Daiichi Sankyo Inc. · Active, not recruiting · NCT04707248
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.